Evidence map›Paper›PMID 9303410›Full record

ArticleAntimicrobial agents and chemotherapy1997

In vitro activity of trovafloxacin against Chlamydia pneumoniae.

P M Roblin, A Kutlin, M R Hammerschlag

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1998
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. The new fluoroquinolones: A critical review.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 1999
    Article
  7. Review
  8. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1998
    Review
  9. Article
  10. Article
  11. Trovafloxacin.Drugs · 1997
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

P M RoblinDepartment of Pediatrics, State University of New York Health Science Center at Brooklyn, 11203, USA.
A Kutlin
M R Hammerschlag
State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, trovafloxacin, and ofloxacin, doxycycline, erythromycin, and azithromycin were determined. The activity of trovafloxacin was similar to that of ofloxacin, with a MIC at which 90% of the isolates are inhibited and a minimal concentration at which 90% of the isolates are killed of 1.0 microg/ml, but trovafloxacin was less active than doxycycline, erythromycin, and azithromycin.

Indexed as

FluoroquinolonesAnti-Bacterial AgentsAnti-Infective AgentsAzithromycinChlamydophila pneumoniaeDoxycyclineErythromycinMicrobial Sensitivity TestsNaphthyridinesOfloxacinAnti-Bacterial AgentsAnti-Infective AgentsAzithromycinDoxycyclineErythromycinFluoroquinolonesNaphthyridinesOfloxacintrovafloxacin

Identifiers

PMID9303410
PMCPMC164061
OpenAlexW2109472152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.